Sotigalimab and/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE trial
2022 · Nature Medicine · 325 citations
https://doi.org/10.1038/s41591-022-01829-9
M
Marco Tognetti
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
38
Papers
942
Citations
9
h-index
9
i10-index
Marco Tognetti is an academic researcher from Biognosys (Switzerland). The author has contributed to research in topics: Advanced Proteomics Techniques and Applications & Pancreatic and Hepatic Oncology Research & Bioinformatics and Genomic Networks. The author has an h-index of 9, co-authored 33 publications.
ORCID: 0000-0002-2379-1525Papers by this author
worksRegulation of DNA repair pathway choice in S and G2 phases by the NHEJ inhibitor CYREN
2017 · Nature · 279 citations
https://doi.org/10.1038/nature24023
MhcVizPipe: A Quality Control Software for Rapid Assessment of Small- to Large-Scale Immunopeptidome Datasets
2021 · Molecular & Cellular Proteomics · 23 citations
https://doi.org/10.1016/j.mcpro.2021.100178
Cell‐to‐cell and type‐to‐type heterogeneity of signaling networks: insights from the crowd
2021 · Molecular Systems Biology · 14 citations
https://doi.org/10.15252/msb.202110402
343 Multiomic biomarker signatures identify subsets of patients who may benefit from either nivolumab or sotigalimab in combination with chemotherapy in metastatic pancreatic cancer
2021 · Regular and Young Investigator Award Abstracts · 1 citations
https://doi.org/10.1136/jitc-2021-sitc2021.343
Unveiling proteomic and peptide-level modifications in cerebrospinal fluid and plasma in normal cognitive aging
2025 · Communications Medicine · 1 citations
https://doi.org/10.1038/s43856-025-01183-0
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat